A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 901–1,000 of 1,000
Matà, S., Torricelli, S., Barilaro, A., Grippo, A., Forleo, P., Mastio, M. D., & Sorbi, S. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117335 · Cited by 6
Hafian, H., Schvartz, H., Patey, M., & Quinquenel, A. (2021) · BMC Oral Health · doi:10.1186/s12903-021-01960-y · Cited by 6
“The risk of progression is approximately 1% per year [6].”
BackgroundChina's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans
Dodlapati, J., Hall, J. A., Kulkarni, P., Reely, K., Nangrani, A. A., & Copeland, L. A. (2022) · Federal Practitioner · doi:10.12788/fp.0303 · Cited by 6
Mitochondrial dysfunction and drug targets in multiple myeloma
Cui, Y., Wang, F., & Fang, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04672-8 · Cited by 7
“The risk progression of MGUS to MM is approximately 1% per year (Kyle et al. 2002).”
BackgroundŠčudla, V., Schneiderka, P., Pika, T., Minařík, J., Bačovský, J., & Farbiaková, V. (2008) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2008.017 · Cited by 6
Mouse Models of Human Mature B-Cell and Plasma Cell Neoplasms
Janz, S., Morse, H. C., & Teitell, M. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_8 · Cited by 6
Hellqvist, E., Kvarnström, M., Söderberg, A., Vrethem, M., Ernerudh, J., & Rosén, A. (2009) · Haematologica · doi:10.3324/haematol.2009.015123 · Cited by 6
Diagnosis and Treatment of Multiple Myeloma
Rajkumar, S. V., & Kyle, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_33 · Cited by 6
Self-citationMonoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma?
Go, R. S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08089.x · Cited by 6
“Fortunately, a long term follow-up study of MGUS showed that at 20 years, the death rate from MM and related malignancies was only 10% (72% from other conditions) (Kyle et al, 2002).”
BackgroundChallenges in Multiple Myeloma Therapy in Older and Frail Patients
Aureli, A., Marziani, B., Sconocchia, T., Pasqualone, G., Franceschini, L., Spagnoli, G. C., Venditti, A., & Sconocchia, G. (2025) · Cancers · doi:10.3390/cancers17060944 · Cited by 5
“…immunoglobulin heavy-chain locus translocations and hyperdiploid karyotypes are already detectable in premalignant phases [5], but only 1% of MGUS cases progress to MM [6], suggesting that the switch to symptomatic disease may be due to sudden, low-frequency, randomly acquired genomic events [7].”
Lee, J., Yoo, S., Yang, S., & Song, S. H. (2025) · Annals of Laboratory Medicine · doi:10.3343/alm.2025.0133 · Cited by 6
Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification
Andersen, L. S., Maeng, C. V., Rögnvaldsson, S., Long, T. E., Brieghel, C., Hermansen, E., Andersen, M. N., Grønbæk, K., Niemann, C. U., Kristinsson, S. Y., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01478-y · Cited by 5
The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists
Marshall, C., Frantz, N., Kikano, E. G., Smith, D. A., Güler, E., Tirumani, S. H., & Ramaiya, N. H. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.21725 · Cited by 6
Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_35 · Cited by 5
Self-citationThe clinical value of monoclonal protein in ANCA-associated vasculitis with renal involvement
Wang, Y., Yang, K., Yu, Z., Huang, Y., He, T., Xiong, J., & Zhao, J. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03579-0 · Cited by 5
“Firstly, although the baseline data of M-protein positive patients in our research had not revealed lymphoproliferative or plasma cell processes, patients with M-protein are more likely to develop hematologic malignancies such as MM and macroglobulinemia [40].”
ResultWonnaparhown, A. M., Hilal, T., Chong, A. C., & Fonseca, R. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101316 · Cited by 6
Corneal Crystals: A Precursor to Cancer
Chou, J., & Sink, M. L. (2011) · Optometry and Vision Science · doi:10.1097/opx.0b013e31820bb227 · Cited by 5
“According to a retrospective, 30-year study by the Mayo clinic in Minnesota, patients with MGUS have a risk of progression of 1% per year for converting to multiple myeloma.(3) This rate of progression does not decrease with time, so patients need to be followed indefinitely.”
BackgroundInfluentialThe Road to Treating Smoldering Multiple Myeloma
Korde, N., Mailankody, S., & Landgren, O. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.012 · Cited by 5
“The risk of MGUS transforming to symptomatic malignancy is 1% per year.(6) Traditional clinical practice depended on careful”
BackgroundGao, M., Yang, G., Kong, Y., Wu, X., & Shi, J. (2015) · BioMed Research International · doi:10.1155/2015/623254 · Cited by 6
Raschle, J., Banz, Y., Suter, T. M., & Pabst, T. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13922 · Cited by 5
Smoldering multiple myeloma: present position and potential promises
Tageja, N., Manasanch, E. E., Korde, N., Kwok, M., Mailankody, S., Bhutani, M., Roschewski, M. J., & Landgren, O. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12205 · Cited by 5
Casanova, M.-L., Makinson, A., Eymard‐Duvernay, S., Ouedraogo, D. E., Badiou, S., Reynes, J., & Tuaillon, É. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000708 · Cited by 6
“3-relative risk [95% confidence interval (CI): 6 to 9] to develop hematologic malignancies, such as lymphoma and multiple myeloma.(14) HIV infection is associated with a dramatic increased incidence of Hodgkin lymphoma (SIR from 3.”
BackgroundMulti-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Ovejero, S., & Moreaux, J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00034 · Cited by 8
“Suffering from MGUS increases the risk of developing MM at a rate of about 1% a year [7].”
BackgroundLeone, P., Malerba, E., Prete, M., Solimando, A. G., Croci, G. A., Ditonno, P., Tucci, M., Susca, N., Derakhshani, A., Dufour, A., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00592-y · Cited by 5
“MM is often preceded by an asymptomatic premalignant condition termed monoclonal gammopathy of undetermined significance (MGUS) [1, 2] that progresses to MM at a rate of approximately 1% per year [3].”
BackgroundJi, M., Shih, Y.-H., Huber, J. H., Wang, M., Feuer, E. J., Etzioni, R., Wang, S., & Chang, S. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-0490 · Cited by 6
How to Identify and Manage High-Risk Smoldering Multiple Myeloma
Mouhieddine, T. H. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01596-5 · Cited by 5
Jerez, A., Ortuño, F. J., Osma, M. D. M., Español, I., González, A. D., Roldán, V., de Arriba, F., & Vicente, V. (2009) · Annals of Medicine · doi:10.1080/07853890903111000 · Cited by 5
“In spite of an eventual compromise of the accuracy of our results due to selection bias, our cohort characteristics at base-line are similar to those found in large population-based studies (2), and the associations found are strong enough to suggest that our results may be extrapolated to most patients with MGUS.”
BackgroundResultInfluentialTakasu, M., Kaichi, Y., Awai, K., Asaoku, H., Kuroda, Y., & Sakai, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.012 · Cited by 5
Prognostic factors in monoclonal gammopathy of undetermined significance
Sackmann, F., Pavlovsky, M. A., Corrado, C., Pizzolato, M., Alejandre, M. E., & Pavlovsky, S. (2007) · Haematologica · doi:10.3324/haematol.11744 · Cited by 6
“The strongest predictor for progression is the serum monoclonal component (MC) concentration.(2,3,4) Other prognostic factors mentioned in the literature are: type of MC,(2,5) level of uninvolved immunoglobulins (UI),(3,6) Bence Jones proteinuria,(3,6) light chain isotype,(4) erythrosedimentation rate (ESR),(6) percen…”
BackgroundMethodResultInfluentialAmyloid Myoneuropathy Mimicking Inclusion Body Myositis
Abuzinadah, A. R., Joseph, J. T., & Korngut, L. W. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013846 · Cited by 5
Goldschmidt, H., Cremer, F. W., Möhler, T., & Ho, A. D. (2003) · Der Internist · doi:10.1007/s00108-003-0920-x · Cited by 5
Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis
Napodano, C., Pocino, K., Gulli, F., Colacicco, L., Santini, S. A., Zuppi, C., & Basile, U. (2016) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22027 · Cited by 5
Munshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Neurological Manifestations of Hematological Disorders
Davies-Jones, G. A. B., & Sussman, J. D. (2008) · Elsevier eBooks · doi:10.1016/b978-044306707-5.50016-x · Cited by 5
Valentine, H., & Dawnay, A. (2021) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632211029327 · Cited by 6
Kitson, A. L., Taylor, A. S., Giacherio, D. A., & Keren, D. F. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab108 · Cited by 5
Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_38 · Cited by 7
Self-citationRenal Disease in Cancer Patients
Finkel, K. W., Lahoti, A., & Foringer, J. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10041-7 · Cited by 5
Leone, P., Solimando, A. G., Prete, M., Malerba, E., Susca, N., Derakhshani, A., Ditonno, P., Terragna, C., Cavo, M., Silvestris, N., et al. (2023) · Cells · doi:10.3390/cells12071011 · Cited by 5
Guenet, L., Decaux, O., Lechartier, H., Ropert, M., & Grosbois, B. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.04.010 · Cited by 7
Cryogloblinaemia type I: serum cryoprecipitate formation at 25 °C
Yagi, Y., Tanioka, M., Kambe, N., Matsumura, Y., KORE-EDA, S., Utani, A., Miyachi, Y., & Kato, M. (2008) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2007.02647.x · Cited by 5
A data base for 3000 monoclonal immunoglobulin cases and a new classification
Pontet, F. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.11.038 · Cited by 5
Varón con anemia ferropénica severa por uncinariasis
Aizpuru, E. M. F., Piney, E. G., Mateo, F. J. N., & González, V. S. (2006) · Anales de Medicina Interna · doi:10.4321/s0212-71992006000900014 · Cited by 5
Free light chains: author's response
Sheldon, J. (2008) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2008.072542 · Cited by 5
Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas
Peinert, S., & Seymour, J. F. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.005 · Cited by 5
“The risk of developing LPL/WM is 46 times higher in patients who have IgM MGUS than in the general population, but what what triggers the progression is unknown.(153)”
BackgroundCytogenetic patterns in multiple myeloma after a phase of preceding MGUS
Kaufmann, H., Ackermann, J., Odelga, V., Sagaster, V., Nösslinger, T., Pfeilstöcker, M., Keck, A. V., Ludwig, H., Gisslinger, H., & Drach, J. W. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01903.x · Cited by 6
Neurologic Complications of Plasma Cell Dyscrasias
Naddaf, E., & Mauermann, M. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_32 · Cited by 5
Late hematological effects in the atomic bomb survivors
Tsukasaki, K., Iwanaga, M., & Tomonaga, M. (2007) · International Congress Series · doi:10.1016/j.ics.2006.10.002 · Cited by 5
Racial disparities in multiple myeloma
Tebuka, E., Rambau, P., & Rasche, L. (2025) · Blood Global Hematology · doi:10.1016/j.bglo.2025.100017 · Cited by 4
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
Waldenström's macroglobulinemia - a review
Coimbra, S., Neves, R., Lima, M., Belo, L., & Santos‐Silva, A. (2014) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.60.05.019 · Cited by 4
Fourdinier, O., Ulrich, M., Karras, A., Olagne, J., Buob, D., Audard, V., Vigneau, C. M., Gibier, J., Guerrot, D., Massy, Z. A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac085 · Cited by 4
Niblock, A. L., Rajendran, S., Laverty, C., Logue, P., & Alexander, H. D. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.12.001 · Cited by 4
Screening for and diagnosis of monoclonal gammopathy
Chong, Y., Lim, S. M., Loh, T. P., Mollee, P. N., Wijeratne, N. G., & Choy, K. W. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208774 · Cited by 4
Ferreira, S. Q., do Amaral, B., Pacheco, J. J., Salazar, F., & Monteiro, L. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092679 · Cited by 4
Ntanasis‐Stathopoulos, I., Koutoulidis, V., Malandrakis, P., Fotiou, D., Spiliopoulou, V., Filippatos, C., Migkou, M., Kanellias, N., Theodorakakou, F., Eleutherakis‐Papaiakovou, E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072224 · Cited by 4
“SMM carries a significantly higher risk of progression to symptomatic MM than MGUS, with an estimated annual progression rate of 10% [2].”
Scleredema with diffuse pigmentation
Minato, H., Nishikori, M., Tanioka, M., Miyachi, Y., & Utani, A. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03320.x · Cited by 4
Vonarx, M., Carpentier, O., Cazin, B., Bouchindhomme, B., & Delaporte, E. (2012) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2012.06.040 · Cited by 4
Could DNA methylation become a useful measure for multiple myeloma prognoses?
Walker, B. A., & Morgan, G. J. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.7 · Cited by 4
Myélome multiple et thrombose veineuse. Quelle thromboprophylaxie faut-il proposer ?
MOREUIL, C. D., Ianotto, J., Eveillard, J., Carrier, M., & Delluc, A. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.12.025 · Cited by 4
Junejo, S. Z., Ali, Y., Lubana, S. S., & Tuli, S. S. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.907041 · Cited by 4
“Results of one large study published in 2002, showed that MGUS was the diagnosis of 2% of patients with ages 350 years and 3% with ages 370 [6].”
BackgroundFunction-based hypothesis testing in censored two-sample location-scale models
Subramanian, S. (2018) · Lifetime Data Analysis · doi:10.1007/s10985-018-09456-8 · Cited by 4
C3 Glomerulonephritis Associated with Monoclonal Gammopathy of Renal Significance
Gomes-Alves, I., & Castro‐Ferreira, I. (2021) · Acta Médica Portuguesa · doi:10.20344/amp.13823 · Cited by 4
How We Manage Smoldering Multiple Myeloma
Romano, A., Cerchione, C., Conticello, C., Martinelli, G., & Raimondo, F. D. (2020) · Hematology Reports · doi:10.4081/hr.2020.8951 · Cited by 4
Gómez, J. M. L., Enciso, B. S., Pollo, M. J. F.-C., García, V. B., & Vera, S. G. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.05.011 · Cited by 4
Kyle, R. A., & Bergsagel, D. E. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-817-5_1 · Cited by 4
Self-citationWaldenstrom’s Macroglobulinemia
Buske, C., & Leblond, V. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-55989-2_10 · Cited by 4
Rudolphi‐Solero, T., Triviño‐Ibáñez, E. M., Jiménez, A. D. G., Ramos-Font, C., Ríos, R., Rebollo-Aguirre, Á. C., & Sánchez, R. S. (2022) · Hematological Oncology · doi:10.1002/hon.3085 · Cited by 4
“Importantly, MGUS is one of the most frequent premalignant disorders, with an annual rate of progression to MM and related neoplasms of around 1%.(18,19) In the present patients, 13 neoplastic processes were detected as an incidental finding (in 3.”
BackgroundUsing Logistic Regression Approach to Predicating Breast Cancer DATASET
Haziemeh, F. A., Darawsheh, S. R., Alshurideh, M. T., & Al-Shaar, A. S. (2023) · Studies in computational intelligence · doi:10.1007/978-3-031-12382-5_31 · Cited by 4
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
Du, C., Li, L., Fan, H., Mao, X., Liu, J., Xu, Y., Sui, W., Deng, S., Li, C., Zhao, J., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2258686 · Cited by 5
MyeloDB: a multi-omics resource for multiple myeloma
Kumar, A., Kumar, K. V., Kundal, K., Sengupta, A., Sharma, S., Kunjulakshmi, R., & Kumar, R. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01280-0 · Cited by 4
“These plasma cells are called "Monoclonal Gammopathy of Undetermined Significance" (MGUS) (4).”
BackgroundInfluentialEffect of adipose tissue on the development of multiple myeloma
Stanisławowski, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10174-8 · Cited by 4
“MGUS, which affects approximately 3% of the population aged ≥ 50 years, can evolve over time and progress to MM [12].”
El-Difrawy, M. M., Zaki, N. E.-S., Marouf, H. M., Ayad, M. W., & Farag, A. M. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0983-8 · Cited by 4
“MGUSs are many times more common than myeloma, estimated to occur in about 3% of individuals over 70 years of age [2].”
Sun, Y., Sandhu, A., Gabaldon, D., Danaraj, J. J., Servilla, K. S., & Tzamaloukas, A. H. (2012) · Case Reports in Nephrology · doi:10.1155/2012/573650 · Cited by 4
Osteoporosis Associated with Cancer Therapy
Heras-Herzig, A., Kozlow, W., Brown, S. A., & Guise, T. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50056-2 · Cited by 5
Amyloidosis: A cancer-derived paraproteinemia and kidney involvement
Małyszko, J., Kozłowska, K., & Małyszko, J. S. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2016.06.004 · Cited by 7
“The diagnosis of hereditary amyloidosis can be difficult since 3 percent of individuals over 50 years of age and 5 percent of individuals over 70 years of age have a monoclonal protein [47].”
BackgroundJahngir, M. U., & Govindarajan, R. (2018) · Cureus · doi:10.7759/cureus.3105 · Cited by 4
Underlying IgM heavy chain amyloidosis in treatment-refractory IgA nephropathy: A case report
Wu, H., Wen, Y.-B., Ye, W., Liu, B.-Y., Shen, K., Gao, R.-T., & Li, M. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i19.3055 · Cited by 4
GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice
Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., Hewett, D. R., & Zannettino, A. C. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228408 · Cited by 5
IgM-MGUS and associated membranoproliferative glomerulonephritis during IVIG administration
Ruhe, J., Gröne, H., Schlosser, M., Kroegel, C., Wolf, G., & Busch, M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04046-x · Cited by 4
Mexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 6
“S(1)27 combinada con bortezomib puede mejorar la SLP en pacientes con t (4;14) o del (17p) y en aquellos con ambas anormalidades.”
BackgroundTherapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Banerjee, S., Amin, S. A., & Jha, T. (2021) · Current Chemical Biology · doi:10.2174/2212796815666210203104446 · Cited by 4
Ferrari, M. F., Lemonakis, K., & Jonsson, M. F. (2021) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2021.1929443 · Cited by 4
“The presence of MGUS is associated with the risk of malignant transformation to MM [19].”
BackgroundHornung, N., Frank, M., Dragano, N., Dürig, J., Dührsen, U., Moebus, S., Erbel, R., Stang, A., Jöckel, K., & Schmidt, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-98803-1 · Cited by 4
Smoldering multiple myeloma: biology, clinical manifestations and management
Nsiala, L., Bobin, A., Lévy, A., Gruchet, C., Sabirou, F., Gardeney, H., Cailly, L., Manier, S., Moya, N., Tomowiak, C., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992615 · Cited by 4
Castañeda‐Avila, M. A., Lapane, K. L., Person, S. D., Zhou, Y., Gurwitz, J. H., Mazor, K. M., & Epstein, M. M. (2022) · Hematological Oncology · doi:10.1002/hon.2992 · Cited by 4
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis
Nuvolone, M., Palladini, G. O., & Merlini, G. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_2 · Cited by 4
Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape
Bhatia, A., & Kumar, Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_16 · Cited by 4
Gammapatía monoclonal de significado incierto
Alejo, E., Puertas, B., & Mateos, M. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.05.006 · Cited by 4
Łuczkowska, K., Kulig, P., Rusińska, K., Baumert, B., & Machaliński, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316780 · Cited by 4
Early Detection of Precursor Diseases of Multiple Myeloma
O’Donnell, E., Borden, B. A., & Ghobrial, I. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.003 · Cited by 4
Estimation of win, loss probabilities, and win ratio based on right‐censored event data
Parner, E. T., & Overgaard, M. T. (2024) · Scandinavian Journal of Statistics · doi:10.1111/sjos.12734 · Cited by 4
“Briefly, a monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2% of persons 50 years of age or older (Kyle et al., 2002).”
Lin, C., & Sung, Y. (2009) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(09)50006-4 · Cited by 4
Loctin, A., Bailly, F., Laroche, D., Tavernier, C., Maillefert, J.-F., & Ornetti, P. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2097-y · Cited by 4
Fouquet, G., Amouzou, K. S., Renaud, L., Carpentier, B., Simonnet, A., de Wyngaert, Z. V., Guidez, S., Demarquette, H., Seynave, M., Deleplanque, D., et al. (2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.10.366 · Cited by 6
Xantogranulomatous Pyelonephritis in children.
Ubetagoyena, M., Martin, M. F., & Sangroniz, L. G. (2014) · PubMed · Cited by 4
Mian, M., Pšenák, O., Greil, R., Fiegl, M., & Tzankov, A. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500399052 · Cited by 4
Barsottini, O. G. P., Arantes, A. D. M., Sigulem, D., Kutner, J. M., Ribeiro, A. A. F., Moura, L. A., & Hamerschlak, N. (2004) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2004000400030 · Cited by 4
Abi-Fadel, F., Desai, N. R., Vatandoust, G., Said, R., Gottesman, A., & Terjanian, T. O. (2010) · Case Reports in Medicine · doi:10.1155/2010/406102 · Cited by 4
“Hindawi Publishing Corporation Case Reports in Medicine Volume 2010, Article ID 406102, 4 pages doi:10.1155/2010/406102”
BackgroundInfluential
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.